BullFrog AI Holdings, Inc.: Nasdaq Delisting Warning – What Investors Need to Know

BullFrog AI Holdings, Inc. (NASDAQ: BFRG) recently received a significant notification from Nasdaq that warrants investor attention. This summary outlines the key details of the event and its potential implications.

---

1. Event Description

BullFrog AI Holdings, Inc. (NASDAQ: BFRG) received an official notice from Nasdaq regarding its common stock. The company's shares traded below the minimum $1.00 bid price for 30 consecutive business days, violating Nasdaq's listing requirements. To maintain its listing, Nasdaq rules mandate that a company's stock price must remain above $1.00.

While BullFrog AI leverages Artificial Intelligence (AI) for drug discovery, this notice does not directly critique its technology. Instead, it signals broader investor concerns about the company's financial performance and its capacity to fund its ambitious drug development pipeline. The sustained trading below the $1.00 threshold suggests the market may be questioning the company's current valuation, its path to profitability, or its progress in advancing drug candidates.

2. Event Date/Timeline

BullFrog AI received the official notice from Nasdaq on February 10, 2026.

The company now has 180 calendar days, until August 10, 2026, to regain compliance. To do so, its common stock must achieve a closing bid price of at least $1.00 for a minimum of ten consecutive business days. If BullFrog AI does not meet this initial requirement, it may qualify for a second 180-day compliance period. This eligibility depends on meeting other Nasdaq listing requirements, such as minimum market capitalization and shareholders' equity, and submitting a formal plan to regain compliance. Such a plan could involve strategies like a reverse stock split (combining multiple shares into one to boost the price per share), strategic partnerships, significant clinical milestones, or new financing efforts. BullFrog AI has stated its intention to monitor the stock price and evaluate all available options to restore compliance and maintain its Nasdaq listing.

3. Impact Assessment

This development is critical because delisting from Nasdaq would significantly reduce the stock's liquidity, making it considerably harder for investors to buy and sell shares. It could also relegate the stock to over-the-counter (OTC) markets, which are less regulated and often deter institutional investors. This loss of visibility and investor confidence could severely impact BullFrog AI's ability to raise crucial capital for its research and development, potentially slowing or even halting its drug discovery efforts.

This event primarily affects investors: If delisted, your shares could become harder to trade. The stock price may also become more volatile as the company works to regain compliance, with a risk of further price declines.

4. Financial Impact

While the notice itself does not immediately affect the listing or trading of BullFrog AI's common stock, the potential for delisting could adversely impact the company's ability to raise capital, increase its cost of capital, and affect the market price and liquidity of its shares. Furthermore, it could hinder the company's ability to attract and retain employees through stock-based compensation programs. BullFrog AI must carefully manage its financial resources and explore options to improve its stock price to mitigate these potential negative financial consequences.

5. Key Takeaways for Investors

For investors, here are the key takeaways:

• Monitor Closely: Expect continued stock price volatility. Observe whether the stock can sustain a price above $1.00.
• Understand Financial Health: This notice highlights the importance of the company's financial runway. While the 8-K filing does not detail specific financials, investors should recognize that a low stock price often correlates with concerns about cash burn, profitability, and the need for future financing. Reviewing BullFrog AI's latest quarterly (10-Q) and annual (10-K) reports for details on cash on hand, operating expenses, and net loss is crucial.
• Delisting Risk is Real: If delisted, trading becomes significantly more difficult, and the stock's value could decline further due to reduced liquidity and investor interest.
• Reverse Stock Split: Be prepared for this potential action. While a reverse stock split increases the share price, it does not change the underlying value of your total investment (fewer shares, higher price per share).
• Strategic Progress: Beyond financial metrics, closely follow any announcements regarding BullFrog AI's AI drug discovery pipeline – including new drug candidates, progress in clinical trials, or significant partnerships. These could be key drivers for regaining investor confidence.
• Company's Plan: Look for concrete actions the company outlines to regain compliance, rather than just monitoring the situation.
• Disclaimer: This information is not financial advice. Always conduct your own due diligence.